Whalesbook
Sanofi India has recommended a final dividend of ₹48 per equity share for the financial year ended December 31, 2025. The company's Board of Directors, meeting on March 25, 2026, also approved the appointment of Mr. Siraj Azmat Chaudhry as an Additional and Independent Director for a five-year term, beginning April 1, 2026.
Shareholders will vote on these key proposals at the company's 70th Annual General Meeting (AGM), scheduled for April 29, 2026. The AGM will be held via video conferencing. The proposed dividend offers a direct return to shareholders, while Mr. Chaudhry's appointment is expected to enhance board expertise and strengthen corporate governance.
Sanofi India is a prominent pharmaceutical company in India, part of the global Sanofi S.A. group, and operates a manufacturing facility in Goa. The company has a consistent history of rewarding its shareholders. In FY2024, a final dividend of ₹117 per equity share was proposed. For FY2025, an interim dividend of ₹75 per share was announced with an ex-date of November 7, 2025. Sanofi India's dividend yield has historically ranged between 2.67% and 3.43%.
This proposed dividend compares favorably to some peers. Sun Pharmaceutical Industries Ltd. has a dividend yield around 0.90%, Dr. Reddy's Laboratories offers about 0.51-0.63%, and Cipla's annual dividend yield is around 1.03-1.27%.
The primary risk is the need for shareholder approval at the 70th AGM for both the final dividend payment and the appointment of Mr. Siraj Azmat Chaudhry. If approved, Mr. Chaudhry will serve his five-year tenure. Investors will be closely tracking the AGM's outcome for confirmation, and the subsequent dividend payment schedule.